Autoinflammatory & rare systemic diseases
Systematic review on the use of biologics in adult-onset still's disease
Authors' conclusion
Safety data from all included studies showed that bDMARDs appear to be a safe alternative to conventional DMARDs.
Study context
- Population
- Patients with adult-onset Still's disease (AOSD)3 randomised controlled trials (RCTs) · 1 retrospective case series · 17 case series
- Comparison
- Biologic disease modifying anti-rheumatic drugs (bDMARDs) vs conventional DMARDs or placebo
- Outcome
- Efficacy and safety of bDMARDs
Pooled result
As reported in the abstract
Efficacy of bDMARDs
- Lack of common assessment criteria; treatment efficacy across studies could not be compared
- Uncontrolled retrospective case series suggested bDMARDs have an effect in AOSD, without comparative data vs other interventions or between bDMARDs
- Evidence that bDMARDs could reduce steroid dose
Safety
- bDMARDs appear to be a safe alternative to conventional DMARDs
Original publication
Systematic review on the use of biologics in adult-onset still's disease. Semin Arthritis Rheum. Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →